Prospect: information for the user
Ticagrelor Intas 60mg film-coated tablets EFG
Read the entire prospectus carefully before starting to take this medication, as it contains important information for you.
even if they have the same symptoms as you, as it may harm them.
Contents of the prospectus
What is Ticagrelor Intas
Ticagrelor Intas contains an active ingredient called ticagrelor. It belongs to a group of medications called antiplatelet agents.
What is Ticagrelor Intas used for
Ticagrelor in combination with acetylsalicylic acid (another antiplatelet agent) should only be used in adults. You have been prescribed this medication because you have had:
This medication reduces the risk of suffering another myocardial infarction, a cerebral infarction, or dying from a heart or blood vessel disease.
How Ticagrelor Intas works
Ticagrelor acts on cells called 'platelets' (also called thrombocytes). These very small blood cells help stop bleeding by clustering to plug small holes in blood vessels that are cut or damaged.
However, platelets can also form clots within damaged blood vessels in the heart and brain. This can be very dangerous because:
Ticagrelor helps prevent platelet aggregation. This reduces the possibility of a blood clot forming that can reduce blood flow.
Do not take Ticagrelor Intas if:
Do not take ticagrelor if you are in any of the above circumstances. If you have doubts, consult your doctor or pharmacist before taking this medication.
Warnings and precautions
Consult your doctor or pharmacist before taking this medication if:
If any of the above applies to your case (or if you are not sure), consult your doctor or pharmacist before taking this medication.
If you are taking ticagrelor and heparin:
Your doctor may require a blood sample for diagnostic tests if they suspect the presence of a rare platelet disorder caused by heparin. It is essential that you inform your doctor that you are taking ticagrelor and heparin, as this medication can affect the diagnostic test.
Children and adolescents
Ticagrelor is not recommended for administration to children and adolescents under 18 years of age.
Other medications and Ticagrelor Intas
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication. This is because ticagrelor can affect the mechanism of action of some medications, and some medications can affect ticagrelor.
Inform your doctor or pharmacist if you are taking any of the following medications:
In particular, inform your doctor or pharmacist if you are taking any of the following medications that increase the risk of bleeding:
Also, inform your doctor that, because you are taking ticagrelor, you may have a higher risk of bleeding if your doctor administers fibrinolytics, often referred to as 'clot dissolvers', such as streptokinase or alteplase.
Pregnancy and breastfeeding
The use of ticagrelor is not recommended if you are pregnant or may become pregnant. Women should use appropriate contraceptive methods to avoid pregnancy while taking this medication.
Consult your doctor before taking this medication if you are breastfeeding. Your doctor will explain the benefits and risks of taking ticagrelor during this period.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medication.
Driving and using machines
Ticagrelor is unlikely to affect your ability to drive or use machines. If you feel dizzy or confused while taking this medication, be careful while driving or using machines.
Sodium content
This medication contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially 'sodium-free'.
Follow the administration instructions of this medication indicated by your doctor exactly. In case of doubt, consult your doctor or pharmacist again.
How much to take
Taking Ticagrelor Intas with other blood coagulation medications
Your doctor will also normally prescribe acetylsalicylic acid. This is a substance present in many medications used to prevent blood coagulation. Your doctor will indicate how much to take (usually between 75-150 mg daily).
How to take Ticagrelor Intas
If you have difficulty swallowing the tablet
If you have difficulty swallowing the tablet, you can crush it and mix it with water as follows:
If you are in the hospital, this tablet may be administered to you mixed with a little water and through a tube through your nose (nasogastric tube).
If you take more Ticagrelor Intas than you should
If you take more ticagrelor than you should, consult your doctor or go to the hospital immediately. Bring the medication packaging with you. You may have a higher risk of bleeding.
If you forget to take Ticagrelor Intas
If you interrupt treatment with Ticagrelor Intas
Do not interrupt this medication without consulting your doctor. Take this medication regularly and for as long as your doctor indicates. If you stop taking ticagrelor, you may increase the risk of suffering another myocardial infarction or a cerebral infarction or dying from a heart or blood vessel disease.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them. With this medication, the following side effects may occur:
Ticagrelor affects blood coagulation, so most side effects are related to bleeding. Bleeding can occur in any part of the body. Some level of bleeding is common (such as bruising and nosebleeds). Severe bleeding is uncommon but can be potentially life-threatening.
Tell your doctor immediately if you notice any of the following - you may need urgent medical treatment:
Consult your doctor if you notice any of the following:
Other possible side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from available data)
? Abnormally low heart rate (normally below 60 beats per minute)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the packaging after EXP/CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Ticagrelor Intas
Core of the tablet: microcrystalline cellulose (E460), sodium croscarmellose (E468), povidone K30, sodium stearyl fumarate.
Coating of the tablets: hypromellose (E464), titanium dioxide (E171), macrogol (E1521), talc (E553B), red iron oxide (E172), black iron oxide (E172).
Appearance of the Product and Container Content
Ticagrelor Intas 60 mg are film-coated tablets of light pink color, round (8 mm in diameter), biconvex, with the inscription «KJ1» on one side.
Ticagrelor Intas 60 mg is presented in blisters containing 14, 56, 60, 100, 168 or 180 film-coated tablets, calendar blisters containing 14, 56 or 168 film-coated tablets, or single-dose precut blisters containing 14 x 1, 56 x 1, 60 x 1, 100 x 1, 168 x 1 or 180 x 1 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Intas Third Party Sales 2005 S.L.
Moll Barcelona s/n, World Trade Center, Edifici Est, 6th Floor
08039 Barcelona
Spain
Manufacturer
Accord Healthcare Polska Sp. z.o.o.
Ul. Lutomierska 50, 95-200,
Pabianice, Poland
or
Accord Healthcare B.V.
Winthontlaan 200, 3526 KV
Utrecht, Netherlands
or
Laboratori Fundació Dau
C/ C, 12-14 Pol.
Ind. Zona Franca,
Barcelona, 08040, Spain
or
Pharmadox Healthcare Limited,
KW20A Kordin Industrial Park,
Paola, PLA 3000,
Malta
Date of Last Revision of this Leaflet: 12/2024
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.